Reynoso Jamie L. sold $39K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 8,750 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.42 on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Oct 5, 2026, 11:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 11:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Bearish
medium confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVBearishLow
01

Why it matters

The modest size of the sale is unlikely to move the stock significantly, but it adds a data point for investors monitoring insider activity.

02

Market read

A routine insider sale with limited market impact; useful for tracking insider sentiment but not a catalyst for immediate price action.

03

What to watch

The CEO's remaining large stake (over 2.7 million shares) still aligns his interests with shareholders.

Relevance 2/10Novelty 2/10Timing: filing today

Background

Form 4 disclosures provide transparent insight into insider transactions. CLOV recently announced a partnership with a major payer, but this filing relates solely to the CEO's personal share sale.

Company-level read

Ticker impact

$CLOVBearishMedium confidence
Context

CEO Reynoso Jamie L. sold 8,750 shares for $38,675 via a 10b5‑1 plan, reducing his stake to 2,794,696 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

Form 4 filings are primary disclosures; the transaction size is modest but the insider is the CEO, which can influence sentiment.

Market effects

Minimal impact on the broader health‑tech sector; the sale is company‑specific.

None

None

Counterpoint

The sale could be routine portfolio rebalancing and not indicative of negative fundamentals.

Key entities

  • Clover Health Investments, Corp.

    US‑listed health‑tech firm (ticker CLOV).

  • Reynoso Jamie L.

    CEO of Clover Health, filing a 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.